QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
QuidelOrtho Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| North America | $1.49B | $1.62B | $1.88B | $2.54B | $1.50B | $1.46B | 54.5% | -8.1% |
| EMEA | $360.70M | $335.80M | $327.30M | $206.80M | $69.60M | $92.90M | 13.2% | +7.4% |
| China | $334.70M | $325.00M | $310.10M | $220.00M | – | – | 12.3% | +3.0% |
| JPAC | $293.00M | $279.40M | $272.70M | – | – | – | 10.7% | +4.9% |
| Latin America | $252.90M | $222.90M | $210.60M | – | – | – | 9.3% | +13.5% |
| China | – | – | $310.10M | $220.00M | $58.00M | $62.40M | – | – |
| Other | – | – | $483.30M | $302.70M | $70.80M | $45.70M | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Domestic | $1.44B | $1.57B | $1.83B | $2.45B | $1.42B | $1.45B | 52.6% | -8.4% |
| Foreign | $1.29B | $1.21B | $1.17B | $814.30M | $283.10M | $209.30M | 47.4% | +6.5% |
From the segment and revenue-disaggregation notes of QuidelOrtho's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.